Arrowhead Pharmaceuticals Inc (ARWR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arrowhead Pharmaceuticals Inc (ARWR) has a cash flow conversion efficiency ratio of 0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($20.49 Million) by net assets ($503.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Arrowhead Pharmaceuticals Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Arrowhead Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Arrowhead Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arrowhead Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arrowhead Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Transsion Holdings Co Ltd
SHG:688036
|
0.157x |
|
Futu Holdings Ltd
NASDAQ:FUTU
|
0.032x |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
0.063x |
|
Dr. Reddy's Laboratories Limited
F:RDDA
|
0.029x |
|
Doosan
KO:000150
|
0.010x |
|
Aecom Technology Corporation
NYSE:ACM
|
0.029x |
|
RHB Bank Bhd
KLSE:1066
|
0.060x |
|
Joby Aviation
NYSE:JOBY
|
-0.074x |
Annual Cash Flow Conversion Efficiency for Arrowhead Pharmaceuticals Inc (1997–2025)
The table below shows the annual cash flow conversion efficiency of Arrowhead Pharmaceuticals Inc from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see Arrowhead Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $503.42 Million | $179.55 Million | 0.357x | +114.72% |
| 2024-09-30 | $191.06 Million | $-462.85 Million | -2.423x | -352.04% |
| 2023-09-30 | $287.16 Million | $-153.89 Million | -0.536x | -64.69% |
| 2022-09-30 | $418.34 Million | $-136.13 Million | -0.325x | -177.70% |
| 2021-09-30 | $408.82 Million | $171.22 Million | 0.419x | +302.75% |
| 2020-09-30 | $461.78 Million | $-95.39 Million | -0.207x | -129.13% |
| 2019-09-30 | $244.04 Million | $173.03 Million | 0.709x | +243.00% |
| 2018-09-30 | $95.24 Million | $-47.22 Million | -0.496x | -67.49% |
| 2017-09-30 | $80.87 Million | $-23.94 Million | -0.296x | +56.34% |
| 2016-09-30 | $95.02 Million | $-64.43 Million | -0.678x | -13.11% |
| 2015-09-30 | $109.62 Million | $-65.71 Million | -0.599x | -180.92% |
| 2014-09-30 | $165.99 Million | $-35.42 Million | -0.213x | +71.15% |
| 2013-09-30 | $25.73 Million | $-19.03 Million | -0.740x | +57.53% |
| 2012-09-30 | $8.81 Million | $-15.34 Million | -1.741x | -305.88% |
| 2011-09-30 | $12.56 Million | $-5.39 Million | -0.429x | +54.98% |
| 2010-09-30 | $8.08 Million | $-7.70 Million | -0.953x | +69.69% |
| 2009-09-30 | $4.86 Million | $-15.28 Million | -3.145x | -40.26% |
| 2008-09-30 | $12.30 Million | $-27.58 Million | -2.242x | -148.54% |
| 2007-09-30 | $26.46 Million | $-23.87 Million | -0.902x | -92.76% |
| 2006-09-30 | $31.61 Million | $-14.79 Million | -0.468x | -44.09% |
| 2005-09-30 | $28.02 Million | $-9.10 Million | -0.325x | -57.54% |
| 2004-09-30 | $11.23 Million | $-2.31 Million | -0.206x | -85.73% |
| 2003-09-30 | $1.42 Million | $-157.60K | -0.111x | -262.64% |
| 2002-09-30 | $-1.55 Million | $-105.83K | 0.068x | +8.82% |
| 2001-09-30 | $-1.30 Million | $-81.81K | 0.063x | -11.57% |
| 2000-09-30 | $-1.13 Million | $-80.09K | 0.071x | +100.61% |
| 1999-09-30 | $-996.10K | $-35.22K | 0.035x | +101.32% |
| 1998-09-30 | $-2.63 Million | $-46.15K | 0.018x | +1091.72% |
| 1997-09-30 | $-2.58 Million | $4.56K | -0.002x | -- |
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, a… Read more